Creabilis appoints Catherine Moukheibir as Chairman of its Board of Directors

Considerable experience to support Company in next important stage of development

Canterbury, UK – 1 June 2015 – Creabilis Ltd, the dermatology company with the most advanced targeted topical treatment in development for chronic pruritus (itch), announces today that it has appointed Catherine Moukheibir as Chairman of its Board of Directors.

Catherine brings wide experience to Creabilis in aligning corporate goals with financial strategy, allowing companies to continue their strong growth trajectories from a position of financial strength. After an initial career in strategy consulting and investment banking in Boston and London, Catherine held several C-Suite level roles in some of Europe's leading biotechnology companies. She was previously Chief Financial Officer of Movetis, a Belgian specialty pharmaceutical company from 2008 to 2010, during which she led the €250 million IPO on Euronext Brussels and subsequent acquisition by Shire for €558 million. Catherine is currently a non-executive Board member of Ablynx (Euronext Brussels: ABLX) and Zealand Pharma (Nasdaq Copenhagen: ZEAL) and a member of the management board of Innate Pharma (Euronext Paris: IPH).

Catherine will lead Creabilis' Board at an exciting time for the Company as it progresses its lead product CT327, a first-in-class selective TrkA kinase inhibitor for the treatment of pruritus (itch) due to psoriasis, a condition where there is no approved standard of care currently. The Company has already reported positive Phase 2b results for CT327 in the treatment of pruritus in psoriasis patients and is now preparing to initiate its Phase III development program.

Catherine Moukheibir, Chairman of the Board of Creabilis, commented: "I am delighted to have been appointed to lead the Creabilis Board at this important time in the Company's development. The potential of CT327 in the treatment of pruritic conditions is a significant opportunity and the data reported so far demonstrates the power of Creabilis' pipeline and its unique Low Systemic Exposure platform technology."

- ENDS -

Notes to Editors:

 

About Creabilis

Creabilis is a dermatology company with the most advanced targeted topical treatment in development for chronic peripheral pruritus (itch). Creabilis has delivered positive Phase 2b results for CT327 in the treatment of pruritus in psoriasis patients. CT327 was developed using Creabilis' proprietary Low Systemic Exposure (LSE) 'topical-by-design' technology that creates molecules optimized for topical applications. Planning for Phase 3 trials with CT327 are underway, with a clear route to the peripheral pruritus market via the initial indication of pruritus due to psoriasis. Creabilis' pipeline also includes CT340, an IND-ready and potent narrow spectrum kinase inhibitor in development for the topical treatment of pruritus of atopic dermatitis.

 

Creabilis is backed by highly respected life science investors Sofinnova Partners, Neomed and AbbVie Biotech Ventures Inc., and is led by an experienced Management team. Creabilis' Corporate Headquarters and Development functions are based in the UK, with Research activities in Italy.

 

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.